Fiegel P, Trenk D, Jaehnchen E, Dieterich H A
Deutsche Klinik für Diagnostik, Wiesbaden, F.R.G.
J Cardiovasc Pharmacol. 1989;14 Suppl 1:S20-3.
The new vasodilator and inotropic drug enoximone was given to dialysis patients as a single intravenous dose of 1 mg/kg. Plasma concentrations were measured up to 240 min. The mother compound enoximone reached a high plasma concentration intravenously, followed by a quick decline of the plasma concentration curve (t1/2 = 1.5 h), comparable to that of normal volunteers. The sulfoxide metabolite, however, had a tremendously prolonged half-life (t1/2 = 7.8 h) in comparison to healthy volunteers (t1/2 = 2.2 h). The volume of distribution of enoximone varies from 0.7-4.8 L/kg with a mean of 2.11 L/kg in comparison to 1.6 L/kg in healthy individuals. The area under the curve (AUC) of enoximone was 815.2 ng/ml/h, and that of the sulfoxide metabolite was 10,200.1 ng/ml/h.
新型血管扩张剂兼强心剂依诺昔酮以1毫克/千克的单次静脉注射剂量给予透析患者。在长达240分钟的时间内测量血浆浓度。依诺昔酮母体化合物静脉注射后达到较高的血浆浓度,随后血浆浓度曲线迅速下降(半衰期t1/2 = 1.5小时),这与正常志愿者的情况相当。然而,与健康志愿者(半衰期t1/2 = 2.2小时)相比,亚砜代谢物的半衰期极大地延长(t1/2 = 7.8小时)。依诺昔酮的分布容积在0.7 - 4.8升/千克之间变化,平均为2.11升/千克,而健康个体为1.6升/千克。依诺昔酮的曲线下面积(AUC)为815.2纳克/毫升/小时,亚砜代谢物的曲线下面积为10200.1纳克/毫升/小时。